About Antiviral Drugs
Antiviral drugs are agents used to cure a viral infection by inhibiting the growth of viral pathogens. There are two types of antiviral agents which includes narrow-spectrum antiviral agents and broad-spectrum antiviral agents.
Technavio’s analysts forecast the global antiviral drugs market to grow at a CAGR of 9.48% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global antiviral drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of antiviral drugs.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Antiviral Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Bristol-Myers Squibb
• F. Hoffmann-La Roche
• Gilead Sciences
• GlaxoSmithKline
Other prominent vendors
• AbbVie
• Johnson & Johnson
• Merck
• Novartis
Market driver
• Stockpiling by public healthcare agencies
• For a full, detailed list, view our report
Market challenge
• Need for proper storage conditions of antiviral drugs
• For a full, detailed list, view our report
Market trend
• Technological advancements
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Research Methodology
PART 03: Introduction
• Key market highlights
• Key vendor offerings
PART 04: Disease Overview
• Viral disease
PART 05: Market landscape
• Market overview
• Five forces analysis
PART 06: Pipeline analysis
PART 07: Market segmentation by therapies
• Global hepatitis therapeutics market
• Global HIV/AIDS therapeutics market
• Global herpes therapeutics market
• Global influenza therapeutics market
PART 08: Market segmentation by MOA
• Reverse transcriptase inhibitors
• Protease inhibitors
• Entry/Fusion inhibitors
• Immune system modulators
PART 09: Geographical segmentation
• Antiviral drugs market in Americas
• Antiviral drugs market in EMEA
• Antiviral drugs market in APAC
PART 10: Decision framework
PART 11: Drivers and challenges
• Market drivers
• Impact of drivers on key customer segments
• Market challenges
• Forcefield analysis of impact of drivers and challenges
PART 12: Market trends
• Technological advancements
• Combination therapy
• Mergers and acquisitions
• Growing partnerships
PART 13: Competitive Landscape
• Competitive scenario
PART 14: Key vendor analysis
• Bristol-Myers Squibb
• F. Hoffmann-La Roche
• Gilead Sciences
• GlaxoSmithKline
• Other prominent vendors
PART 15: Appendix
• List of abbreviations
List of Exhibits
Exhibit 01: Few major products offered by the key vendors
Exhibit 02: HIV treatment regimen approved by FDA
Exhibit 03: Hepatitis treatment regimen approved by FDA
Exhibit 04: Herpes treatment regimen approved by FDA
Exhibit 05: Global antiviral drugs market snapshot
Exhibit 06: Key marketed products
Exhibit 07: Global antiviral drugs market 2016-2021 ($ billions)
Exhibit 08: Opportunity analysis of global antiviral drugs market
Exhibit 09: Snapshot of pipeline molecules (2016)
Exhibit 10: Pipeline analysis
Exhibit 11: Global antiviral drugs market segmentation by therapies
Exhibit 12: Acute hepatitis cases in US 2000-2014
Exhibit 13: Global hepatitis therapeutics market 2016-2021 ($ billions)
Exhibit 14: Global HIV/AIDS therapeutics market 2016-2021 ($ billions)
Exhibit 15: Number of women patients with HSV 2 in US 2000-2014
Exhibit 16: Global herpes therapeutic market 2016-2021 ($ billions)
Exhibit 17: Global influenza therapeutics market 2016-2021 ($ billions)
Exhibit 18: Global antiviral drugs market segmentation by MOA
Exhibit 19: Market share of different segments based on MOA 2016
Exhibit 20: Global antiviral drugs market segmentation by geography 2016 and 2021
Exhibit 21: Global antiviral drugs market revenue by geography 2016-2021 ($ billions)
Exhibit 22: Market scenario in Americas
Exhibit 23: Antiviral drugs market in Americas 2016-2021 ($ billions)
Exhibit 24: Market scenario in EMEA
Exhibit 25: Antiviral drugs market in EMEA 2016-2021 ($ billions)
Exhibit 26: Market scenario in APAC
Exhibit 27: Antiviral drugs market in APAC 2016-2021 ($ billions)
Exhibit 28: Seasonal influenza vaccine: Total doses distributed in millions
Exhibit 29: Impact of drivers
Exhibit 30: Impact of challenges
Exhibit 31: Competitive structure analysis of global antiviral drugs market 2016
Exhibit 32: Competitive analysis of global antiviral drugs market
Exhibit 33: Bristol-Myers Squibb: Geographical segmentation in terms of revenue in 2015
Exhibit 34: Bristol-Myers Squibb: Strength assessment
Exhibit 35: Bristol-Myers Squibb: Strategy assessment
Exhibit 36: Bristol-Myers Squibb: Opportunity assessment
Exhibit 37: F. Hoffman-La Roche: Strength assessment
Exhibit 38: F. Hoffman-La Roche: Strategy assessment
Exhibit 39: F. Hoffman-La Roche: Opportunity assessment
Exhibit 40: Gilead Sciences: Strength assessment
Exhibit 41: Gilead Sciences: Strategy assessment
Exhibit 42: Gilead Sciences: Opportunity assessment
Exhibit 43: GlaxoSmithKline: Strength assessment
Exhibit 44: GlaxoSmithKline: Strategy assessment
Exhibit 45: GlaxoSmithKline: Opportunity assessment
